Pacira BioSciences (PCRX) Common Equity (2010 - 2026)

Pacira BioSciences' Common Equity history runs 17 years deep, the most recent figure standing at $653.9 million for Q1 2026.

• In Q1 2026, Common Equity fell 18.11% year-over-year to $653.9 million; the TTM figure through Mar 2026 stood at $653.9 million (down 18.11% YoY), while the FY2025 annual figure was $693.1 million, down 10.95% from the prior year.
• Common Equity was $653.9 million for Q1 2026 at Pacira BioSciences, down from $693.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $892.2 million in Q1 2024 to a low of $653.9 million in Q1 2026.
• Historically, Common Equity has averaged $777.6 million across 5 years, with a median of $770.1 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Common Equity advanced 16.16% in 2024, then slipped 18.11% in 2026.
• A 5-year view of Common Equity shows it stood at $775.0 million in 2022, then advanced by 12.27% to $870.1 million in 2023, then slipped by 10.55% to $778.3 million in 2024, then decreased by 10.95% to $693.1 million in 2025, then slipped by 5.66% to $653.9 million in 2026.
• The last three Common Equity figures came in at $653.9 million (Q1 2026), $693.1 million (Q4 2025), and $727.2 million (Q3 2025), per Business Quant data.